Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-230 in CAD patients undergoing CABG surgery
NCT07357675Phase 3Recruiting
- Sponsor
- EBI
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of EA-230 in coronary artery disease (CAD), sponsored by EBI. Started Oct 2026; status: recruiting.
02
Drugs
EA-230
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07357675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357675.